Hyperbaric oxygen therapy (HBOT) is one of the few treatments that have proven, with scientific evidence, to be truly effective for fibromyalgia.
In a recent study published by the prestigious medical journal Plos-One, researchers from the University of Tel-Aviv, led by Dr. Eshel Ben-Jacob of the School of Physics and Dr. Shai Efrati of the School of Medical Neuroscience, were able to drastically reduce, or even eliminate, the use of pain medication after treatment with hyperbaric oxygen. They were also able to map regions of the brain that badly process pain and are responsible for the syndrome.
In another published clinical study, the rheumatologist Adelaida García Estiven and her collaborators at the University Hospital of Havana, supported the use of the hyperbaric chamber in the treatment of fibromyalgia, since hyperbaric medicine produces hyperoxia that controls oxidative stress, one of the most relevant factors in the pathophysiology of fibromyalgia.
HBOT has also been shown to be a very effective treatment as a supplement to basic therapies in scleroderma, rheumatoid arthritis, vasculitis, Sjögren's syndrome, systemic lupus erythematosus and other vascular collagen autoimmune diseases. Great experience in this field have in hospitals of countries of the former Soviet Union. There are many published scientific papers (example cited by the Cuban hyperbaric physician Dr. Castellanos Gutierrez: SV Liaguin, VL Lukich, EB Vernekin, HBOT in the treatment of children with systemic sclerodermia. Guiperbaricheskaia fisiologuia and medizina 1999 No. 4, p 24-28 and 1996 No. 3, p 13-18).